Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy

Key Points

• Patients with solid malignancies demonstrate long-term humoral responses to SARS-CoV-2 vaccinations by 12 months.
• Initial impaired antibody responses improved, leading to similar hospitalization rates as healthy individuals.
• Observational analysis across multiple health centers confirms vaccination effectiveness for those undergoing chemotherapy.
• Findings suggest that effective vaccination may benefit patient populations often at risk for severe COVID-19 complications.

Abstract